Abstract: Olefins are epoxidized by hydrogen peroxide in the presence of a modified titanium-containing molecular sieve having a framework structure isomorphous with zeolite beta and comprised of Si, Ti, and Al. The molecular sieve is modified by substituting the aluminum-associated cationic sites with ammonium, alkali metal, or alkaline earth cations instead of protons.

Abstract: Processes for synthesizing tertiary alkynols by reacting carbonyl-group-containing compounds with alkynes in the presence of a basic catalyst are disclosed. Preferred products are 6,10,14-trimethyl-4-pentadecyn-6-ol compounds having the structure: ##STR1## A preferred, novel compound, 6,10,14-trimethyl-4-pentadecyne-2,6-diol, can be used in the synthesis of Vitamin E or Vitamin K.sub.1.

Abstract: In a regulated process wherein propylene is reacted with tertiary butyl hydroperoxide in solution in tertiary butyl alcohol to produce propylene oxide and tertiary butyl alcohol in a reactor system comprising a first isothermal segment comprising a plurality of at least four sequentially interconnected internally cooled reactors, and a second adiabatic segment,an initial feed mixture is continuously charged to the first reactor, comprising propylene and a recycle stream composed of about 25 to about 75 wt.

Abstract: Disclosed is a process for the conversion of conjugated epoxyalkenes to unsaturated alcohols wherein a conjugated epoxyalkene is catalytically hydrogenated in the presence of a sulfur-modified or sulfided nickel catalyst whereby the epoxide ring is hydrogenolyzed without concomitant hydrogenation of the olefinic unsaturation thereby producing allylic and/or homoallylic alcohols.

Abstract: This invention relates to substituted thiazolylaminotetrahydropyridopyrimidines derivatives of the following general formula, the substituent groups of which are as defined in the specification herein: ##STR1## These compounds are useful as inhibitors of platelet aggregation and inhibitors of adhesion molecules and may be provided in pharmaceutical compositions and in methods of treating reperfusion thrombosis injury in patients.

Abstract: A process for producing lower alcohols is presented in which an olefinic feed and H.sub.2 SO.sub.4 react to form a mixture comprising alkyl sulfates, alkyl disulfates, fat acid, and nonpolar hydrocarbons. The mixture is separated into two phases, a nonpolar phase comprising nonpolar hydrocarbons and a polar phase comprising alkyl sulfates, alkyl disulfates, and fat acids. A rag-layer that forms between the nonpolar and polar phases comprising carbonaceous particulate material is removed by contact with an extraction reagent. This can be a slip stream comprising an etheric derivative of the olefinic feed and an oligomeric derivative of the feed which is withdrawn from a subsequent step the process. This forms a separate hydrocarbon phase which is then extracted. The sulfates are then hydrolyzed to form alcohol.

Abstract: The present invention relates to enhanced process for converting certain ethers, such as sec-butyl ether and isopropyl ether to their corresponding reaction products in the presence of water. This may be accomplished by adding a rate enhancing surfactant, such as an anionic or cationic surfactant to a mixture of the ether and water, preferably least about 10.sup.-5 molar surfactant. Under those conditions the reaction shows an increase in reaction rate over the rate of the process wherein surfactant is not used.

Abstract: The invention describes a chromium-free catalyst for hydrogenation of organic compounds, especially organic compounds containing the carbonyl function, such as aldehydes, ketones, or carboxylic acids or their esters, to the corresponding alcohols wherein the catalysts is characterized by the following features:its oxide form corresponds to the compositionCu.sub.a Al.sub.b Zr.sub.c Mn.sub.d O.sub.xwherein the following relations apply:for the first embodiment:a>O; b>O; c.gtoreq.O; d>O; a>b/2; b>a/4; a>c; a>d;and for the second embodiment:a>O; b=a/40 to a/4; c.gtoreq.O; d>O; a>c; a=0.5 d to 0.95 dand x is the number of oxygen ions needed per formula unit for electrical neutrality.

Abstract: Methotrexate, which is a known anticancer agent, can be converted into a polymeric conjugate with a pyran copolymer, which in itself has a certain anticancer effect, by a method in which an alkylene diamine is reacted with the carboxyl group of the methotrexate molecule to give an amidation product having a free amino group in a molecule, which is then reacted with the carboxyl group of the pyran copolymer, of which at least 10% of the repeating units have been modified with the methotrexate residue. The polymeric conjugate has sustained releasability of the methotrexate compound in blood serum so that an excellent therapeutic effect can be obtained by the administration thereof against cancers with little problems due to the side effects caused by an unduly high concentration of the drug in blood unavoidable when methotrexate as such is administrated.

Abstract: A method for preparing tertiary butyl alcohol wherein a feedstock comprising a solution of tertiary butyl hydroperoxide in a cosolvent mixture of tertiary butyl alcohol with isobutane is charged to a hydroperoxide decomposition reaction zone containing a catalytically effective amount of a hydroperoxide decomposition catalyst and is brought into contact with the catalyst in liquid phase with agitation under hydroperoxide decomposition reaction conditions to convert the tertiary butyl hydroperoxide to decomposition products, principally tertiary butyl alcohol.

Abstract: The hydrogenation steps and hydrofinishing steps of the cobalt catalyst oxo process for preparation of the alcohols by the hydroformylation of olefin are carried out using a catalyst containing Ni/Mo on alumina or silica alumina prepared by depositing an organic acid solution of Ni and Mo salts on the support, the acid being phosphorous free.

Abstract: Unsaturated fatty alcohols with 6 to 22 C atoms can be produced by directly hydrating deacidified and/or non-deacidified glyceride oils containing monounsaturated and/or polyunsaturated, straight chain and/or branched-chain fatty acids having 6 to 22 C atoms in the fatty acid residue, by applying a 30 to 100-fold excess of hydrogen in a pressure range from 50 to 300 bars, at temperatures from 200.degree. to 400.degree. C., to zinc-chrome-catalysts of the spinel type, while largely preserving the olefinic double bonds and with formation of propane and 1,2-propylene glycol.

Abstract: Retinoid-like compounds which act as agonists of the RXR retinoid receptor sites induce apoptosis of tumor cells in cell cultures, and are used as drugs to treat tumors in mammals including humans. Compounds which are specific agonists of RXR receptors and also compounds which are agonists of both RAR and RXR agonist (pan-agonists) induce apoptosis, although the RXR agonist compounds are preferred as drugs to avoid undesirable side effects associated with RAR agonist activity. The RXR agonists compounds are administered to mammals afflicted with tumors in pharmaceutical compositions adapted for systemic topical or for intralesional administration. The range of concentration of the active ingredient RXR agonist compound in the pharmaceutical compositions is approximately between 0.001 and 5 percent by weight, and such that the composition delivers approximately 0.1 mg to 100 mg of the active ingredient per kg body weight of the patient, per day of treatment.

Abstract: A method for preparing tertiary butyl alcohol wherein a feedstock comprising a solvent solution of tertiary butyl hydroperoxide in tertiary butyl alcohol or a mixture of tertiary butyl alcohol with isobutane is charged to a hydroperoxide decomposition reaction zone containing a catalytically effective amount of a hydroperoxide decomposition catalyst consisting essentially of alumina having gold-promoted palladium deposited thereon and is brought into contact with the catalyst in liquid phase with agitation under hydroperoxide decomposition reaction conditions to convert the tertiary butyl hydroperoxide to decomposition products, principally tertiary butyl alcohol.

Abstract: The present invention provides paclitaxel derivatives of formula I ##STR1## in which R.sup.1 is --COR.sup.z, in which R.sup.z is RR.sup.o N--, RHN--, RO-- or R;R.sup.2 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, or a radical of the formula --W--R.sup.x in which W is a bond, C.sub.2-6 alkenediyl, or --(CH.sub.2).sub.t --, in which t is one to six; and R.sup.x is naphthyl, phenyl, or heteroaryl, and furthermore R.sup.x can be optionally substituted with one to three same or different C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen or --CF.sub.3 groups;R and R.sup.o are independently C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl, C.sub.2-6 alkynyl, or phenyl, optionally substituted with one to three same or different C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen or --CF.sub.3 groups.Also provided by this invention are pharmaceutical formulations (compositions) and a method of treating mammalian tumors with a compound of formula I.

Abstract: The present invention pertains to antagonists of excitatory amino acid neurotransmitter receptor antagonists, their method of preparation as well as compositions containing them which have the general formula: ##STR1## wherein n and m independently are 0, 1, 2, or 3; R.sub.1 is selected from the group consisting of hydrogen and R.sub.2 ; R.sub.2 is selected from the group consisting of hydrogen, halogen, halomethyl, nitro, amino, alkoxy, hydroxyl, hydroxymethyl, C.sub.1 to C.sub.6 lower alkyl, C.sub.7 to C.sub.12 higher alkyl, aryl and aralkyl, wherein if R.sub.2 is hydrogen, R.sub.1 is not hydrogen; R.sub.3 is selected from the group consisting of hydrogen and C.sub.1 to C.sub.6 lower alkyl; the stereoisomers thereof in their resolved or racemic form, and pharmaceutically acceptable salts thereof.

Abstract: Organic hydroperoxides are decomposed by drying a reaction mixture containing the organic hydroperoxide and an organic solvent and contacting the dried reaction mixture with a metal organic ligand catalyst under hydroperoxide decomposition conditions. An organic co-solvent for the hydroperoxide may also be used.

Abstract: A process for preparing alkenols of the formula IR.sup.1 --CH.dbd.CH(CH.sub.2).sub.n OH Iwhere R.sup.1 is hydrogen or a hydrocarbon radical, and n is an integer from 3 to 15,a) by reacting a phosphonium salt of the formula IIaR.sup.1 --CH.sub.2 --P.sup.+ (C.sub.6 H.sub.5).sub.3 X.sup.-IIawhere X is chlorine, bromine or iodine, with an aldehyde of the formula IIIa or its hemiacetal of the formula IIIb ##STR1## or b) by reacting a phosphonium salt of the formula IIb(C.sub.6 H.sub.5).sub.3 P.sup.+ (CH.sub.2).sub.n+1 OH X.sup.-IIbwith a aldehyde of the formula IVR.sup.1 CHO IVin a solvent in the presence of a base, wherein the base is the alkali metal salt of an alcohol and the solvent is an alcohol.

Abstract: A process for the preparation and purification of nitroaromatics by nitration of the corresponding aromatics and subsequent melt crystallization. The residual melts which occur are recycled.

Abstract: Disclosed is a process for the homogeneous, catalytic hydrogenation of epoxyalkenes and epoxycycloalkenes, especially conjugated .gamma.,.delta.-epoxyalkenes and .gamma.,.delta.-epoxycycloalkenes, to the corresponding epoxyalkanes and epoxycycloalkanes using a solution of a complex rhodium catalyst whereby the olefinic unsaturation is hydrogenated without significant hydrogenolysis of the conjugated epoxy group.